|
|
Article: Sanofi pasteur Cell Culture-Based Seasonal Influenza Vaccine Enters First Clinical Trial.
- Article from:
- PR Newswire
- Article date:
- September 26, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Flu Vaccine Based on New Technology within U.S. Government Preparedness Program
SWIFTWATER, Pa., and LYON, France, Sept. 26 /PRNewswire-FirstCall/ -- Sanofi pasteur, the vaccines business of the sanofi-aventis Group , initiated its first clinical study today with a new generation of seasonal influenza vaccine produced using cell culture technology. This trial represents one of the company's initiatives to diversify flu vaccine manufacturing technologies.
The trial conducted in the United States is part of a contract awarded by the U.S. Department of Health and Human Services (HHS) to accelerate the development of a new cell culture-based influenza ...